Medical device company OncoSil Medical (ASX:OSL), which is focused on localised treatments for patients with pancreatic and liver cancer, has been granted Ethics Approval by Monash Health for its OncoPaC global clinical study program for pancreatic cancer.
The Ethics Approval at Monash Health will facilitate ethics approval for other participating study centres Australia-wide (except in Western Australia).
The successful grant of Ethics Approval at Monash Health comes after the company filed its Ethics Committee (HREC) submission in November last year. Monash Health is the largest public health service in Melbourne, and has agreed to be the lead Australian study centre. It provides health care services to more than 1.5 million people.
To date, OncoSil Medical has confirmed the participation of 12 centres for its global pancreatic clinical study program, and is currently in discussions with a further seven centres in the UK, Europe and Australia. The company says it will progressively add new centres to its trial program over the coming months, and will also progressively commence patient recruitment globally into the study.
“We are extremely pleased to have secured Ethics Approval for our global OncoPaC clinical study program in pancreatic cancer at Monash Health," said CEO Daniel Kenny. "Monash is a highly regarded cancer centre and is also the lead Australian centre for our clinical study program. With Ethics Approval granted at Monash, it now paves the way for the provision of ethics approvals across other Australian study centres, a pivotal requirement in the study program.”